A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

125 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-09-15

Study Completion Date

2016-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to understand the treatment patterns in patients with Pulmonary Arterial Hypertension (PAH) or Chronic Thromboembolic Pulmonary Hypertension (CTEPH) during a switch of treatment to Adempas in real-life clinical practice.

In addition, this study will describe patient demographics and reason for switching

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

NCT01784562

Hypertension, Pulmonary

NO_LONGER_AVAILABLE

An Open Multiple Dose Titration Study In Patients With Pulmonary Hypertension

NCT00454558

Hypertension, Pulmonary

COMPLETED PHASE2

A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.

NCT02759419

Hypertension, Pulmonary

COMPLETED PHASE4

A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.

NCT00855465

Pulmonary Hypertension

COMPLETED PHASE3

A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction

NCT01065454

Hypertension, Pulmonary Ventricular Dysfunction, Left

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension, Pulmonary

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BAY63-2521

Patients who have been switched from a Pulmonary Hypertension treatment to Adempas

Riociguat (Adempas, BAY63-2521)

Intervention Type DRUG

As per the treating physicians discretion

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Riociguat (Adempas, BAY63-2521)

As per the treating physicians discretion

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- Female and male adult patients diagnosed with PAH or inoperable/recurrent/persistent CTEPH who have been switched from a PH treatment (i.e. Endothelin Receptor Antagonist(ERAs), Phosphodiesterase-5 inhibitor(PDE5i) or Prostacyclin Analog (PCA) to Adempas

Exclusion Criteria

* Patients participating in an investigational program with interventions outside of routine clinical practice
* Patients who have not switched their therapy from an Endothelin Receptor Antagonist (ERA) or Prostacyclin Analog (PCA) but received Adempas purely as an add-on therapy

Eligible Sex

ALL

Accepts Healthy Volunteers

No